These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 34550112

  • 1. Treatment of Clostridioides difficile infection.
    Med Lett Drugs Ther; 2021 Sep 06; 63(1632):137-141. PubMed ID: 34550112
    [No Abstract] [Full Text] [Related]

  • 2. Live fecal microbiota oral capsules (Vowst) for prevention of CDI recurrence.
    Med Lett Drugs Ther; 2023 May 29; 65(1677):81-82. PubMed ID: 37216198
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Firvanq--vancomycin oral solution.
    Med Lett Drugs Ther; 2018 Jul 16; 60(1551):122. PubMed ID: 30036349
    [No Abstract] [Full Text] [Related]

  • 5. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E, Cornely OA, Ramos-Martinez A, Plesniak R, Ellison MC, Hanson ME, Dorr MB.
    Eur J Clin Microbiol Infect Dis; 2020 Oct 16; 39(10):1933-1939. PubMed ID: 32504314
    [Abstract] [Full Text] [Related]

  • 6. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE, Urquiaga M, Alonso CD, Kelly CP.
    Anaerobe; 2020 Feb 16; 61():102098. PubMed ID: 31493500
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H, Tateda K, Yanagihara K, Kusachi S, Takesue Y, Miki T, Oizumi Y, Gamo K, Hashimoto A, Toyoshima J, Kato K.
    J Infect Chemother; 2018 Sep 16; 24(9):744-752. PubMed ID: 29934056
    [Abstract] [Full Text] [Related]

  • 8. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.
    Prabhu VS, Cornely OA, Golan Y, Dubberke ER, Heimann SM, Hanson ME, Liao J, Pedley A, Dorr MB, Marcella S.
    Clin Infect Dis; 2017 Oct 01; 65(7):1218-1221. PubMed ID: 30060024
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J, Gong CL, Hitchcock MM, Holubar M, Deresinski S, Hay JW.
    Clin Microbiol Infect; 2021 Oct 01; 27(10):1448-1454. PubMed ID: 33878506
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland.
    Oksi J, Aalto A, Säilä P, Partanen T, Anttila VJ, Mattila E.
    Eur J Clin Microbiol Infect Dis; 2019 Oct 01; 38(10):1947-1952. PubMed ID: 31359254
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.
    Olmedo M, Kestler M, Valerio M, Padilla B, Rodríguez González C, Chamarro E, Machado M, Álvarez-Uría A, Alcalá L, Muñoz P, Bouza E.
    Rev Esp Quimioter; 2022 Jun 01; 35(3):279-283. PubMed ID: 35279984
    [Abstract] [Full Text] [Related]

  • 14. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
    Deeks ED.
    Drugs; 2017 Oct 01; 77(15):1657-1663. PubMed ID: 28865041
    [Abstract] [Full Text] [Related]

  • 15. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
    Manthey CF, Eckmann L, Fuhrmann V.
    Expert Rev Clin Pharmacol; 2017 Nov 01; 10(11):1239-1250. PubMed ID: 28766951
    [Abstract] [Full Text] [Related]

  • 16. Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives.
    Cymbal M, Chatterjee A, Baggott B, Auron M.
    Am J Med; 2024 Jul 01; 137(7):571-576. PubMed ID: 38508330
    [Abstract] [Full Text] [Related]

  • 17. Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence.
    Escudero-Sanchez R, Ramos-Martínez A, Caballero-Bermejo AF, Díaz-Pollán B, Ruiz-Carrascoso G, Samperio MO, García PM, Amador PM, Romo FG, Segarra OM, Jiménez GN, Del Campo Albendea L, García AM, Cobo J.
    Eur J Clin Microbiol Infect Dis; 2024 Mar 01; 43(3):533-540. PubMed ID: 38236366
    [Abstract] [Full Text] [Related]

  • 18. ▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.
    Drug Ther Bull; 2018 May 01; 56(5):57-60. PubMed ID: 29760164
    [Abstract] [Full Text] [Related]

  • 19. Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment.
    Shen J, Mehrotra DV, Dorr MB, Zeng Z, Li J, Xu X, Nickle D, Holzinger ER, Chhibber A, Wilcox MH, Blanchard RL, Shaw PM.
    mSphere; 2020 May 06; 5(3):. PubMed ID: 32376702
    [Abstract] [Full Text] [Related]

  • 20. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
    Mikamo H, Aoyama N, Sawata M, Fujimoto G, Dorr MB, Yoshinari T.
    J Infect Chemother; 2018 Feb 06; 24(2):123-129. PubMed ID: 29097028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.